We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Therapeutic Delivery – Products

Compendium

Applications and Innovations in Cell and Gene Therapy

Access this exclusive compendium for a selection of Technology Networks’ most popular content in this rapidly developing topic area including infographics, listicles, talk recordings and more.

More Lipid Nanoparticles
Whitepaper

Unlocking More Lipid Nanoparticle Insights

Developing mRNA-based therapeutics is complex work, requiring highly skilled scientists, high-tech microfluidics platforms and sophisticated analytical equipment, and of course the mRNA itself.
Nanoparticle
App Note / Case Study

Rapid 4D Analysis of Lipid Nanoparticle Components

Lipid nanoparticles (LNPs) have emerged as effective delivery vehicles for mRNA vaccines and nucleic acid-based drugs. Hence, the analysis of their composition, stability, and biological interactions is essential in drug development and delivery.
A microfluidic system.
Product News

Particle Works Is Optimizing mRNA-LNP Formulation

Particle Works is making major contributions to the field of nanomedicine by producing automated microfluidic systems with the potential to improve efficiency in the nanotherapeutic drug development pipeline.
Distinguishing Oxidative Impurities From Ionizable Lipids Used in LNP Formulations content piece image
App Note / Case Study

Distinguishing Oxidative Impurities From Ionizable Lipids Used in LNP Formulations

Lipid nanoparticles (LNPs), comprised of ionizable lipids, are used to deliver oligonucleotides to work as therapeutics or to stimulate the immune system, as in the initial mRNA-based COVID vaccines.
Collection of cells floating in a blue background.
Product News

MaxCyte Signs Strategic Platform License With Curamys To Enable Cell and Gene Therapies for the Treatment of Rare Intractable Diseases

Under the terms of the agreement, Curamys obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.
A scientist wearing a white lab coat and blue gloves looks at a piece of equipment.
Product News

Sartorius BIA Separations and Exopharm Sign Joint Research Agreement To Develop Integrated Technology for Large-Scale Exosome Production

Sartorius BIA Separations and Exopharm Ltd. have announced they had entered into a formal collaboration.
ALiS, the latest innovation from Particle Works.
Product News

Particle Works Launches ALiS – An Automated and High-Throughput Platform for LNP Formulation Screening

Particle Works continues to pave the way for particle perfection with the highly anticipated launch of its second revolutionary platform, the Automated Library Synthesis (ALiS) System.
Nine different drug capsules in a horizontal line, each a different colour.
Product News

Lonza Launches New Capsule To Deliver Acid-Sensitive Active Pharmaceutical Ingredients to the Intestine

Lonza has launched an innovative new capsule solution for intestinal (enteric) drug delivery.
Distinguishing Oxidative Impurities From Ionizable Lipids Using Electron Activated Dissociation content piece image
App Note / Case Study

Distinguishing Oxidative Impurities From Ionizable Lipids Using Electron Activated Dissociation

Lipid nanoparticles (LNPs) comprised of ionizable lipids can be used to deliver oligonucleotides to work as therapeutics or to stimulate the immune system. Detailed and sensitive characterization of the ionizable lipid and its related impurities is necessary to ensure quality, however, obtaining the level of detail needed is challenging with current LC-MS-based methodologies.
Advertisement